Detailed Narrative
International Markets Drive Growth
Alembic's international business was the primary growth engine in Q1 FY26. The US business grew 13% YoY, aided by volume gains and four new product launches, while the Rest of World (RoW) segment surged 21%. Management expects the US to maintain at least 10% growth per quarter for the remainder of the year, supported by a pipeline of 10-15 additional launches.
Domestic Branded Business Undergoes Correction
The India branded business grew by a modest 5% to ₹599 crores, which management termed as 'under-delivery'. The slowdown is attributed to a strategic shift toward stricter sales monitoring (primaries vs. secondaries) and alignment with UCPMP norms. Management is confident that execution gaps will be resolved within months, aiming to return to double-digit growth.
API Segment Faces Pricing and Transparency Headwinds
The API business remained flat at ₹261 crores, impacted by pricing erosion that has persisted for 6-7 quarters. A unique challenge highlighted was the leakage of Indian export data through Chinese traders, which has compromised pricing confidentiality. Management expects a tough couple of quarters before a slow recovery in this segment.
R&D Investment and Pipeline Strategy
R&D spending reached ₹145 crores (8.5% of revenue) and is on track to hit the annual target of ₹600-650 crores. The company is pivoting toward complex injectables and peptides. While they missed the first wave for Semaglutide in the US, they are targeting RoW markets and planning a 'Day 1' launch for Tirzepatide in the US.
Operational Efficiency and Margin Expansion
Gross margins improved to 76.2% due to a better product mix and cost improvement programs. EBITDA margins (post-R&D) stood at 17%, benefiting from improved utilization of new facilities. The company expects further margin expansion as capacity utilization increases in the injectable, oncology, and new OSD facilities.